A Modern Approach to the Treatment of Cancer and Other Serious Diseases

At Nativis we’re making targeted, non-invasive treatment a reality. Our technology has the potential to effectively fight cancer and other diseases with few or no adverse effects. How is this possible?


Note: Nativis Voyager® ulRFE™ System for rGBM is an investigational medical device. Limited by Federal (or United States) law to investigational use only.

Founded in 2002 and headquartered in Seattle, WA, Nativis is a clinical-stage bio-electronics company. Nativis has invented and patented a groundbreaking technology that utilizes precisely targeted, ultra-low radio frequency energy (ulRFE) to specifically regulate metabolic pathways on the molecular and genetic levels – without chemicals, radiation or drugs – delivered via a simple-to-use non-invasive device called Nativis Voyager®.

The company’s goal is to transform disease treatment on a global scale with ulRFE. The proprietary technology has the potential to be applied to a wide range of conditions and other health-related needs (including agriculture, bio-fuels and veterinary medicine, to name a few).

Nativis’ initial focus is on the treatment of patients with brain cancer (initially, recurrent glioblastoma) who are not well served by conventional standard of care therapies, which often result in poor outcomes and devastating side effects. Additional pre-clinical work is being completed for melanoma, lung cancer, liver cancer, inflammatory disease and chronic pain.

Scientific Platform

Our proprietary ultra-low Radio Frequency Energy (ulRFE) technology produces a cognate of solvated molecules by measuring and recording their surface electrostatic surface potential as an oscillating magnetic field. The ulRFE cognate is delivered locally and non-systemicaly via a medical device. Pre-clinical and clinical studies suggest the ability to specifically modulate metabolic pathways and/or replicate known mechanisms of action for proven commercial drugs. To date, no adverse effects or toxicity related to the device have been observed in human clinical trials.

See Our Science